个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共28条记录   Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies [作者：Lee, EC; Fitzgerald, M; Bannerman, B; Donelan, J; Bano, K; Terkelsen, J; Bradley, DP; Subakan, O; Silva, MD; Liu, R; Pickard, M; Li, Z; Tayber, O; Li, P; Hales, P; Carsillo, M; Neppalli, VT; Berger, AJ; Kupperman, E; Manfredi, M; Bolen, JB; Van Ness, B; Janz, S,期刊：Clinical Cancer Research, 页码：7313-7323 , 文章类型： Article，,卷期：2011年17-23] Purpose: The clinical success of the first-in-class proteasome inhibitor bortezomib (VELCADE) has validated the proteasome as a therapeutic target for treating human cancers. MLN9708 is an investigational proteasome inhi... Inhibition of the Notch-Hey1 Axis Blocks Embryonal Rhabdomyosarcoma Tumorigenesis [作者：Belyea, BC; Naini, S; Bentley, RC; Linardic, CM,期刊：Clinical Cancer Research, 页码：7324-7336 , 文章类型： Article，,卷期：2011年17-23] Purpose: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood and remains refractory to combined-modality therapy in patients with high risk disease. In skeletal myogenesis, Notch signaling prevents... Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance [作者：Gotink, KJ; Broxterman, HJ; Labots, M; de Haas, RR; Dekker, H; Honeywell, RJ; Rudek, MA; Beerepoot, LV; Musters, RJ; Jansen, G; Griffioen, AW; Assaraf, YG; Pili, R; Peters, GJ; Verheul, HMW,期刊：Clinical Cancer Research, 页码：7337-7346 , 文章类型： Article，,卷期：2011年17-23] Purpose: Resistance to antiangiogenic tyrosine kinase inhibitors such as sunitinib is an important clinical problem, but its underlying mechanisms are largely unknown. We analyzed tumor sunitinib levels in mice and patie... Gene Expression Differences between Colon and Rectum Tumors [作者：Sanz-Pamplona, R; Cordero, D; Berenguer, A; Lejbkowicz, F; Rennert, H; Salazar, R; Biondo, S; Sanjuan, X; Pujana, MA; Rozek, L; Giordano, TJ; Ben-Izhak, O; Cohen, HI; Trougouboff, P; Bejhar, J; Sova, Y; Rennert, G; Gruber, SB; Moreno, V,期刊：Clinical Cancer Research, 页码：7303-7312 , 文章类型： Article，,卷期：2011年17-23] Purpose: Colorectal cancer studies typically include both colon and rectum tumors as a common entity, though this assumption is controversial and only minor differences have been reported at the molecular and epidemiolog... CDKN2A/B Alterations Impair Prognosis in Adult BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients [作者：Iacobucci, I; Ferrari, A; Lonetti, A; Papayannidis, C; Paoloni, F; Trino, S; Storlazzi, CT; Ottaviani, E; Cattina, F; Impera, L; Abbenante, MC; Vignetti, M; Vitale, A; Potenza, L; Paolini, S; Soverini, S; Pane, F; Luppi, M; Foa, R; Baccarani, M; Martinelli, G,期刊：Clinical Cancer Research, 页码：7413-7423 , 文章类型： Article，,卷期：2011年17-23] Purpose: The 9p21 locus, encoding three important tumor suppressors (p16/CDKN2A, p14/ARF, and p15/CDKN2B), is a major target of inactivation in the pathogenesis of many human tumors.Patients and Methods: To explore, at h... Molecular Imaging of TGF beta-Induced Smad2/3 Phosphorylation Reveals a Role for Receptor Tyrosine Kinases in Modulating TGF beta Signaling [作者：Nyati, S; Schinske, K; Ray, D; Nyati, M; Ross, BD; Rehemtulla, A,期刊：Clinical Cancer Research, 页码：7424-7439 , 文章类型： Article，,卷期：2011年17-23] Purpose: The dual modality of TGF beta, both as a potent tumor suppressor and a stimulator of tumor progression, invasion, and metastasis, make it a critical target for therapeutic intervention in human cancers. The abil... Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells [作者：Fiskus, W; Verstovsek, S; Manshouri, T; Rao, R; Balusu, R; Venkannagari, S; Nalabothula, NR; Ha, K; Smith, JE; Hembruff, SL; Abhyankar, S; McGuirk, J; Bhalla, KN,期刊：Clinical Cancer Research, 页码：7347-7358 , 文章类型： Article，,卷期：2011年17-23] Purpose: We determined the activity of hsp90 inhibitor, and/or Janus-activated kinase 2 (JAK2) tyrosine kinase inhibitor (TKI), against JAK2-V617F-expressing cultured mouse (Ba/F3-JAK2-V617F) and human (HEL92.1.7 and UKE... Preclinical Testing of PI3K/AKT/mTOR Signaling Inhibitors in a Mouse Model of Ovarian Endometrioid Adenocarcinoma [作者：Wu, R; Hu, TC; Rehemtulla, A; Fearon, ER; Cho, KR,期刊：Clinical Cancer Research, 页码：7359-7372 , 文章类型： Article，,卷期：2011年17-23] Purpose: Genetically engineered mouse (GEM) models of ovarian cancer that closely recapitulate their human tumor counterparts may be invaluable tools for preclinical testing of novel therapeutics. We studied murine ovari... Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma [作者：Park, SI; Shenoi, J; Frayo, SM; Hamlin, DK; Lin, YK; Wilbur, DS; Stayton, PS; Orgun, N; Hylarides, M; Buchegger, F; Kenoyer, AL; Axtman, A; Gopal, AK; Green, DJ; Pagel, JM; Press, OW,期刊：Clinical Cancer Research, 页码：7373-7382 , 文章类型： Article，,卷期：2011年17-23] Purpose: Pretargeted radioimmunotherapy (PRIT) using streptavidin (SAv)-biotin technology can deliver higher therapeutic doses of radioactivity to tumors than conventional RIT. However, "endogenous" biotin can interfere ... Molecular Insights on the Peripheral and Intratumoral Effects of Systemic High-Dose rIL-2 (Aldesleukin) Administration for the Treatment of Metastatic Melanoma [作者：Weiss, GR; Grosh, WW; Chianese-Bullock, KA; Zhao, YD; Liu, H; Slingluff, CL; Marincola, FM; Wang, E,期刊：Clinical Cancer Research, 页码：7440-7450 , 文章类型： Article，,卷期：2011年17-23] Purpose: We have previously shown that within tumors, recombinant interleukin-2 (rIL-2, aldesleukin) consistently activates tumor-associated macrophages and upregulates IFN-stimulated genes while inducing minimal migrati... Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced Melanoma [作者：Kim, KB; Chesney, J; Robinson, D; Gardner, H; Shi, MM; Kirkwood, JM,期刊：Clinical Cancer Research, 页码：7451-7461 , 文章类型： Article，,卷期：2011年17-23] Purpose: Dovitinib (TKI258) is an orally available inhibitor of fibroblast growth factor (FGF), VEGF, and platelet-derived growth factor receptors. This phase I/II dose-escalation study was conducted to evaluate the safe... Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma [作者：Fruehauf, J; Lutzky, J; McDermott, D; Brown, CK; Meric, JB; Rosbrook, B; Shalinsky, DR; Liau, KF; Niethammer, AG; Kim, S; Rixe, O,期刊：Clinical Cancer Research, 页码：7462-7469 , 文章类型： Article，,卷期：2011年17-23] Purpose: This multicenter, open-label, phase II study evaluated the safety and clinical activity of axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, ... Enhanced Antitumor Efficacy of Low-Dose Etoposide with Oncolytic Herpes Simplex Virus in Human Glioblastoma Stem Cell Xenografts [作者：Cheema, TA; Kanai, R; Kim, GW; Wakimoto, H; Passer, B; Rabkin, SD; Martuza, RL,期刊：Clinical Cancer Research, 页码：7383-7393 , 文章类型： Article，,卷期：2011年17-23] Purpose: Glioblastoma (GBM) inevitably recurs despite surgery, radiation, and chemotherapy. A subpopulation of tumor cells, GBM stem cells (GSC), has been implicated in this recurrence. The chemotherapeutic agent etoposi... ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors [作者：Heuckmann, JM; Holzel, M; Sos, ML; Heynck, S; Balke-Want, H; Koker, M; Peifer, M; Weiss, J; Lovly, CM; Grutter, C; Rauh, D; Pao, W; Thomas, RK,期刊：Clinical Cancer Research, 页码：7394-7401 , 文章类型： Article，,卷期：2011年17-23] Purpose: EML4-ALK fusions define a subset of lung cancers that can be effectively treated with anaplastic lymphoma kinase (ALK) inhibitors. Unfortunately, the duration of response is heterogeneous and acquired resistance... The Reconstruction of Transcriptional Networks Reveals Critical Genes with Implications for Clinical Outcome of Multiple Myeloma [作者：Agnelli, L; Forcato, M; Ferrari, F; Tuana, G; Todoerti, K; Walker, BA; Morgan, GJ; Lombardi, L; Bicciato, S; Neri, A,期刊：Clinical Cancer Research, 页码：7402-7412 , 文章类型： Article，,卷期：2011年17-23] Purpose: The combined use of microarray technologies and bioinformatics analysis has improved our understanding of biological complexity of multiple myeloma (MM). In contrast, the application of the same technology in th... Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy [作者：Zaanan, A; Flejou, JF; Emile, JF; Des Guetz, G; Cuilliere-Dartigues, P; Malka, D; Lecaille, C; Validire, P; Louvet, C; Rougier, P; de Gramont, A; Bonnetain, F; Praz, F; Taieb, J,期刊：Clinical Cancer Research, 页码：7470-7478 , 文章类型： Article，,卷期：2011年17-23] Purpose: Adding oxaliplatin to adjuvant 5-fluorouracil (5-FU) chemotherapy improves 3-year disease-free survival (DFS) after resection of stage III colon cancer. Several studies suggest that patients with tumors exhibiti...